Alethio Therapeutics
Private Company
Funding information not available
Overview
Alethio Therapeutics is a private, preclinical-stage biotech spin-out from the University of Oxford, founded in 2019 and based in Cambridge, UK. The company is focused on developing first-in-class, disease-modifying therapies for myeloproliferative neoplasms (MPNs), a group of incurable chronic blood cancers. Its pipeline is driven by the ARTEMIS platform, which integrates a vast repository of patient-derived data, advanced 'omics, and organoid models to identify and de-risk novel targets. Alethio emerged from stealth in late 2025 with two ADC programs and appointed a new CEO and Chair to advance its lead candidate towards clinical studies.
Technology Platform
ARTEMIS: A proprietary discovery and development engine that integrates one of the world's largest MPN patient tissue repositories, advanced 'omics, machine learning, and disease-relevant human bone marrow organoid models to identify, validate, and de-risk novel therapeutic targets.
Opportunities
Risk Factors
Competitive Landscape
The MPN treatment landscape is evolving beyond JAK inhibitors. Competitors include companies developing next-generation JAK inhibitors, BET inhibitors, telomerase inhibitors, and other targeted agents. Alethio's differentiation lies in its specific focus on ADCs targeting clone-specific antigens and its deep foundational biology from its Oxford founders.